New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...

RSV season is beginning, but for the first time, parents can access an effective treatment to protect their infants from this common but dangerous virus.

Now that colder temperatures have arrived, the Illinois Department of Public Health (IDPH) is reminding Illinoisans to ...

Cases of respiratory syncytial virus, or RSV, are widespread across the area – even as providers at Pediatric Care Specialists continue seeing young patients for a continued trend of "walking ...

The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...

Your child may have RSV. RSV or respiratory syncytial virus is a common seasonal infection usually peaking in January. This condition is most noticeable in our young patients. Their airways are ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

Newborns whose mothers have not received the RSV vaccine, should receive Nirsevimab between October and March. Public health leaders stress one of the best ways to reduce transmission of viruses is to ...

The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...